LGND Ligand Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 78

Relative Strength: Rel. Strength: 89

Relative Valuation: Rel. Valuation: 50

Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $7.9

Last Report Period Date: Mar 31, 2026

According to the most recent financial data from March 2026, the current EPS (TTM) is $7.9. Ligand Pharmaceuticals's EPS for 2025 came in at $6.44, marking an increase from -$0.22 in 2024. For the quarterly period ending on Mar 31, 2026, LGND's EPS was -$0.67.

LGND earnings history

Historical annual and quarterly earnings per share (EPS) data for Ligand Pharmaceuticals

EPS (TTM)

$7.9

EPS Growth YoY (Quarterly)

69.7%

EPS (Quarterly)

-$0.67

EPS Growth (Quarterly)

-128.8%

Ligand Pharmaceuticals had an annual EPS of $6.44, marking an increase of 3,027.3% from -$0.22 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was -$0.67, marking a 69.7% increase from the same quarter last year. LGND's TTM EPS stands at $7.9 as of March 2026. Ligand Pharmaceuticals's EPS for 2024 stood at -$0.22, a 107.3% decrease from 2023.

LGND earnings chart

LGND EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

69.7%

EPS growth YoY

3,027.3%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Ligand Pharmaceuticals has recorded an increase in EPS of 69.7% over the last 12 months (YoY, quarterly). Across the last decade, LGND had an average annual EPS growth of -5.7%.

LGND Earnings Waterfall

Breakdown of revenue, profit and net income for Ligand Pharmaceuticals

LGND Earnings vs Peers

What are the earnings of LGND compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
BMY Bristol Myers Squibb Co	15.55	178.7%	5.3%	N/A
PFE Pfizer Inc	18.87	-3.5%	-37.4%	-3.7%
AMGN Amgen Inc	23.96	88.1%	5.6%	2.9%
JNJ Johnson & Johnson	27.39	90.6%	17.7%	14.8%
MRK Merck & Co Inc	33.5	8%	8.4%	21.2%
LGND Ligand Pharmaceuticals Inc	35.37	3,027.3%	N/A	N/A
LLY ELI LILLY & Co	39.27	95.6%	49.2%	27.5%
BAX Baxter International Inc	N/A	-47.2%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.